



Life.  
Science.



SOLUTION PAPER —

# DynamicARC®

The Next Revolution in Proton Therapy

FASTER · SIMPLER · SHARPER



# Introduction ---

Proton therapy has brought meaningful benefits to cancer treatment and is considered the most advanced form of radiation therapy available today.

IBA is committed to making proton therapy accessible to all patients who could benefit from it, through meaningful and sustainable clinical and technical evolutions that will facilitate its adoption and increase its value. DynamicARC\* is an important step on this journey to ensure proton therapy reaches its full potential.

DynamicARC consists in simultaneous gantry rotation and beam delivery at variable energies; allowing faster, sharper and simpler treatment workflow. This new treatment modality represents the largest improvement since the evolution from Double Scattering to Pencil Beam Scanning in proton therapy.

To deliver the promise of DynamicARC, IBA has initiated a global DynamicARC Consortium (DAC), in collaboration with leading clinical centers. Together with the Consortium and our Clinical Advisory Board, we are working to bring DynamicARC to life to increase patient throughput.

In this Solution Paper, we look back at the history of arc therapy and share how its future clinical implementation with DynamicARC will improve the treatment landscape. We hope it will help you better understand the opportunities that lie ahead and how you can confidently embrace the future of proton therapy with DynamicARC on the Proteus® platform.




**SOFIE GILLIS**

**Clinical Solutions Director**

*IBA Proton Therapy, Louvain-la-Neuve, Belgium*

\*DynamicARC is the registered brand of IBA's Proton Arc therapy solution which is currently under research and development. DynamicARC will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.



# Table of contents

---

<b>THE HISTORY OF ARC THERAPY</b>	<b>6</b>
The evolution of radiotherapy	6
The evolution of proton therapy	8
Proton arc therapy: the beginnings	9
<b>THE PROMISE OF DynamicARC</b>	<b>10</b>
Principle	10
Consortium	10
Ecosystem	11
<b>DynamicARC: TOWARDS SHARPER, FASTER AND SIMPLER TREATMENT</b>	<b>12</b>
Sharper	12
Faster	15
Simpler	15
<b>DynamicARC: CLINICAL INDICATIONS</b>	<b>16</b>
Overview of key studies in different indications	17
<b>CONCLUSION</b>	<b>19</b>
<b>REFERENCES</b>	<b>21</b>

# The history of arc therapy

---

There have been significant advances in the delivery of radiotherapy and proton therapy since they were first introduced.

Over the past decades, progress in treatment planning systems and linear accelerator delivery capabilities have led to improved dose distributions and conformity<sup>1</sup>. Imaging techniques have also become increasingly sophisticated, which has resulted in improved accuracy of target volume definition and delineation<sup>2</sup>.

One of the most recent advances in radiotherapy is the development of arc therapy. With arc therapy, radiation is delivered with a continuous rotation of the radiation source. This allows the patient to be treated with continuous beam delivery as the gantry rotates.

## The evolution of radiotherapy

In radiotherapy, the development of intensity modulated radiotherapy (IMRT) has been an important milestone. IMRT employs variable intensity across multiple radiation beamlets which allows the construction of highly conformal dose distributions. The benefits of this technique include improved target volume dose conformity and sparing of normal tissues and organs at risk<sup>3,4,5</sup>.

However, IMRT has some limitations such as the greater complexity and treatment delivery time compared to conventional conformal radiotherapy. IMRT plans also use a larger number of monitor units, resulting in an increase in the amount of low dose radiation to the rest of the body of the patient. As such, there have been some concerns of increased risk of secondary radiation-induced malignancies<sup>6,7,8</sup>.

Arc therapy sets out to overcome some of the

limitations of IMRT. The introduction of Volumetric Modulated Arc Therapy (VMAT) has significantly changed the treatment landscape in conventional radiotherapy, allowing the user to achieve highly conformal dose distributions with improved target volume coverage and sparing of normal tissues compared with standard IMRT<sup>9</sup>. VMAT also offers other advantages, such as reduced treatment delivery time. Today, VMAT is widely used by radiotherapy centers.

However, VMAT also has limitations<sup>10</sup>. Challenges in clinical practice include achieving lower integral dose, greater dose conformity and better sparing of organs at risk.

## Radiotherapy milestones

1943

First LINAC installation in the UK

1960s

Adoption of 2D radiotherapy

1992

First commercial use of IMRT

1995

General adoption of IMRT

2005

General adoption of VMAT

## Proton therapy milestones

1980s

First proton therapy facilities with scattering techniques

2008

Clinical use of IMPT/PBS

2018

First proton arc therapy proof of concept

## The evolution of proton therapy

Since its inception, proton therapy has been increasingly used to treat a variety of cancers. Proton therapy offers excellent physical properties and superior dosimetric characteristics<sup>11</sup>. It can increase patient survival by improving the local tumor control<sup>12</sup> while reducing injury to normal tissues, which may result in fewer radiation-induced adverse effects.

Just like photon-based radiotherapy, proton therapy has been evolving to offer greater efficiency and better outcomes. This includes the development of Intensity Modulated Proton Therapy (IMPT) based on Pencil Beam Scanning (PBS) proton therapy, which IBA was the first to introduce on a commercial equipment and which has since then become the standard in proton therapy.

In PBS, the proton beam paints the target volume, one layer at a time, voxel by voxel, to precisely match the shape of the tumor. It allows the user to give a different dose to each voxel of the map. IMPT treats a small section of the tumor at a time, adjusting the proton beam dose and depth to wider and narrower contours of the tumor, section by section. Combined with the appropriate imaging devices and treatment strategies, IMPT is also capable of treating moving tumors<sup>13</sup>.

Today, the next frontier in proton therapy is the development of proton arc therapy which has the potential to further improve dose conformity and distribution, and to optimize treatment delivery time<sup>14</sup>.



*Rotational protons have been a dream for many years. But it was never possible to implement it before. Beaumont, in collaboration with IBA, has developed a novel technology which will allow scanning beam protons to be delivered in a rotational technique.*



### **DR CRAIG STEVENS**

**Chief of Radiation Oncology**

Corewell Health (then Beaumont), Royal Oak, Michigan, United States



## Proton arc therapy: the beginnings

In 1997, Deasy et al suggested the use of arc therapy in protons using the distal edge tracking principle<sup>15</sup>: “It is proposed to deliver proton therapy in a ‘tomotherapy’ geometry; that is, by moving an intensity-modulated slit proton beam around the patient in a helical pattern”.

An early study showing the potential of proton arc therapy to improve dose conformity was published in 2013, looking at non-small cell lung cancers<sup>16</sup>. Seco et al concluded: **“Stereotactic body radiation therapy with proton arc and photon-VMAT generate significantly more conformal high-dose volumes than standard proton SBRT, without loss of coverage of the tumor and with significant sparing of nearby organs,** such as chest wall. In addition, both proton arc approaches spare the healthy lung from low-dose radiation relative to photon VMAT. Our data suggest that IMPT-arc should be developed for clinical use.”

The first proton spot-scanning arc optimization method compatible with existing proton therapy systems was described by Ding and al in 2016 using a ProteusONE system<sup>17</sup>. It was “based on an interactive approach, solving the main obstacles in proton arc therapy, producing plans with fine control point sampling spacing for potential continuous arc delivery; robust plan quality with a practical achievable delivery time; and finally, a reasonable plan workflow and plan calculation time”.

In 2018, IBA in partnership with Corewell Health (formerly William Beaumont Hospital) successfully performed the first prototype of dynamic proton arc delivery on a ProteusONE proton therapy system<sup>18</sup>. The study conclusions were that “the measurements and simulations demonstrated the feasibility of spot-scanning arc treatment within the clinical requirements.”



# The promise of DynamicARC

## DynamicARC principle

IBA's DynamicARC program aims to bring the full potential of proton arc therapy to clinicians and patients, making treatment sharper, faster and simpler and contributing to greater proton therapy accessibility for patients who could benefit from it.

With DynamicARC, treatment is delivered during gantry rotation. As of today, the patient positioning system and couch remain fixed throughout the arc delivery.

To optimize delivery time and dose conformity, the gantry speed is variable as well as the energy delivered. The gantry decelerates when many spots must be delivered in a short angle span. On the contrary, the gantry accelerates when few or no spots need to be delivered in a larger angle span.

In a nutshell, DynamicARC allows dynamic continuous irradiation while the gantry is rotating, with the advantages of both PBS and Bragg Peak without the exit dose.



CLICK OR SCAN THE QR CODE TO WATCH OUR DynamicARC VIDEO

IBA was granted a patent for this unique technology.



*DynamicARC proton therapy offers a more targeted approach compared to photon-based techniques. It provides more flexibility in optimizing the conformity of the treatment to the tumor and will streamline further the treatment delivery improving drastically the patient experience.*



**PR HANS LANGENDIJK**

**Radiation Oncologist**

University Medical Center Groningen (UMCG), Netherlands

## DynamicARC consortium

Committed to shaping the future of proton therapy together with its users, IBA has initiated a global DynamicARC Consortium, in collaboration with eight leading clinical centers who are pioneers in proton therapy. The Consortium is a unique platform to exchange and tackle the application challenges to make DynamicARC a successful clinical reality. The members of the Consortium are highly experienced clinicians, physicians, and physics representatives from leading international centers:

### Consortium members



\*January 2024 - this list may be subject to changes.

## DynamicARC ecosystem

To support DynamicARC and obtain the full benefits in clinical practice, IBA is working on developing a DynamicARC ecosystem by integrating with Oncology Information Systems (OIS), Treatment Planning Systems (TPS) and dosimetry solutions.

Treatment Planning Systems for DynamicARC are an active research area, with a growing number of scientific publications. They are decisive to fully benefit from the potential advantages of DynamicARC. Like for VMAT, treatment planning for DynamicARC is streamlined, removing the need for complex beam arrangements<sup>19</sup>. It also allows delivery time reduction<sup>20</sup> and linear-energy-transfer (LET) optimization<sup>21</sup>.



Several algorithms and methods on arc optimization are being researched at the moment, with a focus on conformity and speed. IBA is working closely with two partners, Elekta and RaySearch Laboratories, to ensure the commercial availability of Treatment Planning Solutions for DynamicARC at launch.

In addition, IBA Proton Therapy teams are collaborating closely with IBA Dosimetry on integrated machine and patient dosimetry tools to support DynamicARC. These include nozzle and couch holders for calibration, commissioning, Machine QA and Patient QA detectors (Phoenix, Sphinx Compact, Zebra, Giraffe and MatrixX). Patient-specific log-based QA is also currently being developed, thanks to the integration of the read-out of the gantry angle in the Proteus system logs.


**PHOENIX**



**SPHINX**



**MATRIX X**



**MYQA ION**

# DynamicARC: towards sharper, faster and simpler treatment

DynamicARC has the potential to significantly improve treatment delivery.

## Sharper


DynamicARC could make treatment sharper by delivering an expected lower integral dose and offering better dose conformity<sup>10</sup>.

In oropharyngeal cancer patients for example, in the model-based approach as practiced in the Netherlands<sup>22</sup>, DynamicARC allows to qualify 78% of patients compared to 64% of patients with IMPT, which represents a **14 points** [i.e. 22%] increase in patient qualification.

# +22%

Patients qualified for PT with DynamicARC compared to conventional IMPT and VMAT, in the model-based approach

### Patient selection process: model-based selection (2018-2021) oropharyngeal cancer (n=230)



**PAT: Proton Arc Therapy**


**NTCP: Normal Tissue Complication Probability**

% shown on the graphic are relative percentages

**CASE STUDY 1:**  
**BREAST TUMOR: OAR SPARING (COPLANAR STUDY)<sup>23</sup>**


Intensity-Modulated Proton Therapy (IMPT)

IBA DynamicARC



**2 FIELDS IMPT  
 2 ISOCENTERS  
 WITH GRADIENT MATCHING**

**1 SINGLE ISOCENTER  
 ARC OF 160°**



A feasibility study by Chang et al<sup>24</sup> has shown that proton arc therapy can reduce the dose delivered to organs at risk and the probability of normal tissue complications in patients treated for left-sided whole breast radiotherapy.

**CASE STUDY 2:**

**NASOPHARYNGEAL CARCINOMA: BETTER CONFORMALITY & DOSE DISTRIBUTION**



VMAT [photons]

IMPT [protons]  
Current technique

Arc [protons]  
New technique

Courtesy of Prof Langendijk - UMC Groningen (UMCG), The Netherlands

UMCG research on head & neck patients has shown an at least 14.2% reduction in NTCP grade 2 compared to VMAT, with the potential to qualify more patients for proton therapy<sup>25</sup>.

*Research shows that DynamicARC may also allow to optimize linear-energy-transfer (LET)<sup>21</sup> and may help mitigating interplay effects for moving tumors<sup>26</sup>. The better dose conformity offered by DynamicARC may favor the move to ultra-hypofractionation in proton therapy<sup>27</sup>.*



## **Faster**

With an optimized workflow, DynamicARC can be faster than IMPT, allowing for higher patient throughput. The gain in treatment time is due to the reduction in the number of beams (i.e. 2-5 static beams replaced by 1-2 arcs), removing time for re-positioning and re-imaging between beams, while delivering one arc is longer than delivering one static beam for the same volume.

A retrospective study was conducted by Corewell Health<sup>28</sup> on 21 patients treated with IMPT, representative of the typical case mix of the proton therapy center. For each patient, a DynamicARC plan was produced, with similar or better characteristics than the corresponding IMPT plan. The team then estimated the irradiation time for each arc plan using an internal model benchmarked on their current ProteusONE solution. The total delivery time for the 21 patients was added up and compared to IMPT plans.

An average **reduction of 60% of fraction delivery time per patient** was observed. Considering the same set-up time, if all patients treated with IMPT were treated with DynamicARC. The biggest advantages were seen in the longer treatments, where DynamicARC can have a significant impact in time.

# Up to 30%

more patients could be treated on a typical treatment day.

## **Simpler**

DynamicARC is simpler than IMPT, in the same way that VMAT is simpler than IMRT in conventional radiotherapy. Rotational delivery can significantly simplify treatment planning and delivery workflows in proton therapy centers.

**1 BEAM PLANNING**


**1 BEAM QA**

**1 BEAM DELIVERY**

With DynamicARC, there is no need for complex beam arrangements, as the Treatment Planning System will offer automatic angle optimization for dose conformity. It is a **linac-like operation** avoiding multiple fields adjustments with only one beam delivered, the removal of a lot of couch kicks and less need for accessories.

# DynamicARC: clinical indications

DynamicARC is expected to be beneficial to a wide range of clinical indications.



**More than 150 patient cases\*, across 10 studies, have already compared plans with DynamicARC on ProteusONE and other treatment modalities.**

These studies have shown that:

- In brain and head & neck cancer, DynamicARC has the potential to significantly reduce the dose to OARs (except for small central lesions in the brain).
- In large breast cancer, DynamicARC has the potential to greatly simplify the workflow (increase of the lateral field size) and reduce toxicities.
- In thoracic cancer, DynamicARC has the potential to mitigate the interplay effect.
- In abdominal and pelvic cancer, DynamicARC will allow a potentially more favorable LET distribution.

\*September 2023



## Overview of key studies in different indications

### **Brain cancer**

- Proton arc therapy could significantly reduce the dose delivered to the hippocampus and cochlea in patients being treated with whole-brain radiotherapy<sup>29</sup>.
- In addition, proton arc therapy has a dosimetric advantage in the V12Gy and R50 with target volumes > 9.00 cc compared to VMAT and IMPT<sup>27</sup>. A significant clinical benefit was found in deep centrally located lesions larger than 20.00 cc using proton arc therapy because of the superior dose conformity and mean dose reduction in healthy brain tissue. Nine retrospective clinical cases and a blind survey showed good agreement with the in silico dosimetric model and decision tree. Additionally, proton arc therapy significantly reduced the treatment delivery time compared to VMAT.

### **Breast cancer**

- The proton arc therapy technique can further reduce the dose delivered to OARs and the probability of normal tissue complications in patients treated for left-sided whole breast radiotherapy<sup>24</sup>. In addition, when the target size is large, multiple isocenters are required in IMPT (which means moving the couch and acquiring additional images between fields), while proton arc therapy can reduce that need.

### **Head & neck cancer**

- Proton arc therapy could significantly spare OARs while providing a similar or more robust target coverage compared with IMPT in the treatment of bilateral HNC<sup>30,31</sup>. Proton arc therapy does not need to use Range Shifter while providing a superior dosimetric plan quality and simplifying the clinical workflow with a practically achievable treatment delivery time compared to the current standard-of-care IMPT. Additionally, the total integral dose is lower in proton arc therapy than in IMPT.

### **Lung cancer**

- Proton arc therapy could further improve the dosimetric results in patients with locally advanced-stage non-small-cell lung cancer (NSCLC) and potentially be implemented into routine clinical practice<sup>26</sup>.
- Proton arc therapy can allow to effectively mitigate the interplay effect for proton lung SBRT compared to IMPT with repainting and is associated with normal tissue sparing<sup>32</sup>. It may make delivery of proton SBRT more technically feasible and less complex with fewer concerns over underdosing the target compared to other proton therapy techniques.

### **Prostate cancer**

- The first systemic dosimetric approach on the concept of proton arc therapy in the treatment of prostate cancer patients demonstrated the potential of SPArc\* to not only provide a more robust and improved plan quality but also to reduce the beam delivery time into a practical, achievable time<sup>33</sup>.

\* SPArc: proton arc therapy by Corewell Health

### **Spine metastases**

- Proton arc therapy is an advanced planning and treatment technique to push the dosimetric limits over the current PBS technique method<sup>34</sup>. Compared to IMPT, proton arc therapy further improved the target coverage conformity and robustness. Compared to the VMAT technique, proton arc therapy would be more efficient, meanwhile providing equivalent and better dosimetric plan quality for spine SBRS.

### **Across indications: LET**

- Using proton arc therapy for LETd-based optimization is feasible and has significant advantages<sup>21</sup>. It could maximize the LETd distribution wherever is desired inside the target and averts the high LETd away from the adjacent critical organs-at-risk.

### **Across indications: treatment planning optimization algorithms**

- Treatment planning methods have shown the ability to produce high-quality treatment plans in a few minutes, making them suitable for the clinical introduction of DynamicARC<sup>19</sup>.
- Including delivery time in the plan optimization can effectively reduce the treatment time and increase patient throughput, thereby reducing the operation cost of proton therapy<sup>35</sup>.
- The application of bi-criteria optimization to the proton arc therapy problem permits the planners to select the best treatment strategy according to the patient conditions and clinical resources available<sup>36</sup>.
- The first proton arc therapy planning framework allows to directly optimize plan quality with the delivery time as an input for the new generation of proton therapy systems<sup>37</sup>. This work paved the road for implementing the technology in a routine clinic and provided a planning platform to explore the trade-off between the delivery time and plan quality.
- The first fast-planning framework for proton arc therapy spot-sparsity optimization enables efficient treatment delivery with a balanced plan quality<sup>38</sup>. This work paved the road for clinical implementation in the TPS platform efficiently.

# Conclusion ---

DynamicARC enables the delivery of proton beams while the gantry is rotating. It allows to deliver faster treatments, to further improve dose conformity and spare normal tissues. It also promises a simpler workflow, getting closer to LINAC-like operations. It could change the future of proton therapy, allowing to increase patient qualification and throughput so more patients can benefit from precise proton cancer care.

IBA is fully committed with its clinical and industrial partners to make DynamicARC a clinical reality, available on our Proteus proton therapy system. We are also developing an integrated ecosystem providing all the tools you need to support this new technology and help you embrace this revolution with confidence while ensuring the profitability of your investment. We will share our milestones on this journey; watch our announcements to learn about our progress!

As always, IBA is fully committed to the upgradability and sustainability of its solutions. As such, a significant proportion of our installed base will be able to upgrade to DynamicARC under specific technical and financial conditions. Together, let's change the future of cancer care for patients and those who care for them!

# References

1. Thwaites DI, Tuohy JB. Back to the future: the history and development of the clinical linear accelerator. *Phys Med Biol* 2006;51:R343–62 [[PubMed](#)].
2. Newbold K et al. Advanced imaging applied to radiotherapy planning in head and neck cancer: a clinical review. *Br J Radiol* 2006;79:554–61 [[PubMed](#)].
3. Staffurth J. Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy. *Clin Oncol* 2010;22:643–57 [[PubMed](#)].
4. Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part I. *Br J Radiol* 2004;77:88–96 [[PubMed](#)].
5. Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part II. *Br J Radiol* 2004;77:177–82 [[PubMed](#)].
6. Hall EJ, Wu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys* 2003;56:83–8 [[PubMed](#)].
7. Verellen D, Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. *Radiother Oncol* 1999;53:199–203 [[PubMed](#)].
8. Ruben JD et al. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. *Int J Radiat Oncol Biol Phys* 2008;70:1530–6 [[PubMed](#)].
9. Teoh M et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. *Br J Radiol*. 2011 Nov;84(1007): 967-96. [[PubMed](#)]
10. de Jong B et al. Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model-based clinic. *Radiotherapy and Oncology* (2023). [[PubMed](#)]
11. Tian X et al. The evolution of proton beam therapy: Current and future status. *Mol Clin Oncol*. 2018 Jan;8(1):15-21. [[PubMed](#)]
12. Palm RF et al. The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base. *Cancer*. 2019 Feb 15;125(4):642-651. [[PubMed](#)]
13. Chang JY et al. Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. *Int J Radiat Oncol Biol Phys*. 2017 Sep 1;99(1):41-50. [[PubMed](#)]
14. First irradiation of a Spot Scanning Proton Arc Therapy plan at Beaumont Health. Proton Therapy IBA. [www.youtube.be/oeG0GNBiLTi?si=uSI8hUOR01sGkhFQ](http://www.youtube.be/oeG0GNBiLTi?si=uSI8hUOR01sGkhFQ).
15. Deasy JO et al. "Comformal Proton Tomotherapy Using Distal Edge Tracking." *Radiotherapy and Oncology* 37 (1995): S43. [https://doi.org/10.1016/017-8140\(96\)80599-8](https://doi.org/10.1016/017-8140(96)80599-8).
16. Seco J et al. "Proton Arc Reduces Range Uncertainty Effects and Improves Conformality Compared with Photon Volumetric Modulated Arc Therapy in Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer." *International Journal of Radiation Oncology Biology Physics* 87, no. 1 (2013): 188–94. <https://doi.org/10.1016/j.ijrobp.2013.04.048>.
17. Ding X et al. "Spot-Scanning Proton Arc (SPArc) Therapy – The First Robust and Delivery-Efficient Spot-Scanning Arc Therapy." *International Journal of Radiation Oncology • Biology • Physics* 0, no. 0 (2016): 1107–16. <https://doi.org/10.1016/J.IJROBP.2016.08.049>.
18. Li X et al. "The First Prototype of Spot-Scanning Proton Arc Treatment Delivery." *Radiotherapy and Oncology* 137 (2019): 130–36. <https://doi.org/10.1016/j.radonc.2019.04.032>.
19. Engwall E et al. Fast robust optimization of proton PBS arc therapy plans using early energy layer selection and spot assignment. *Phys Med Biol*. 2022 Mar 17;67(6). [[PubMed](#)]

20. Liu G et al. First direct machine-specific parameters incorporated in Spot-scanning Proton Arc (SPArc) optimization algorithm. *Med Phys.* 2024 Aug;51(8):5682-5692. [[PubMed](#)]
21. Li X et al. Linear Energy Transfer Incorporated Spot-Scanning Proton Arc Therapy Optimization: A Feasibility Study. *Front Oncol.* 2021 Jul 12;11:698537. doi: 10.3389/fonc.2021.698537. PMID: 34327139; PMCID: PMC8313436. [[Frontiers](#)]
22. de Jong B et al. Both S. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients. *Med Phys.* 2023 Mar;50(3):1305-1317. [[PubMed](#)]
23. Ding et al. PTCOG 58 (2019).
24. Chang S et al. Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy. *Radiat Oncol* 15, 232 (2020). <https://doi.org/10.1186/s13014-020-01676-3>
25. Ongoing study at UMG presented at NAPT 2022. IBA Campus. <https://www.campus-iba.com/webinars/napt-2022>
26. Li X et al. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy. *Radiat Oncol.* 2018 Feb 27;13(1):35. doi: 10.1186/s13014-018-0981-6. PMID: 29486782; PMCID: PMC6389253. [[PubMed](#)]
27. Chang S et al. Redefine the Role of Spot-Scanning Proton Beam Therapy for the Single Brain Metastasis Stereotactic Radiosurgery. *Front Oncol.* 2022 May 19;12:804036. doi: 10.3389/fonc.2022.804036. PMID: 35664795; PMCID: PMC9160604.
28. Gang et al. The First Modeling of the Spot-Scanning Proton Arc (SPArc) Delivery Sequence and Investigating Its Efficiency Improvement in the Clinical Proton Treatment Workflow, AAPM 2021
29. Ding X et al Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. *Acta Oncol.* 2019 Apr;58(4):483-490. [[PubMed](#)]
30. Liu G et al. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study. *Radiat Oncol.* 2020 Jan 30;15(1):21. [[PubMed](#)]
31. de Jong BA et al. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients. *Med Phys.* 2023 Mar;50(3):1305-1317. [[PubMed](#)]
32. Liu G et al. Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study. *Front Oncol.* 2021 Apr 22;11:664455. [[PubMed](#)]
33. Ding X et al. Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. *Acta Oncol.* 2018 Mar;57(3):435-437. [[PubMed](#)]
34. Liu G et al. Is proton beam therapy ready for single fraction spine SBRS? - a feasibility study to use spot-scanning proton arc (SPArc) therapy to improve the robustness and dosimetric plan quality. *Acta Oncol.* 2021 May;60(5):653-657. [[PubMed](#)]
35. Liu G et al. A novel energy sequence optimization algorithm for efficient spot-scanning proton arc (SPArc) treatment delivery. *Acta Oncol.* 2020 Oct;59(10):1178-1185. [[PubMed](#)]
36. Wuyckens S et al. Bi-criteria Pareto optimization to balance irradiation time and dosimetric objectives in proton arc therapy. *Phys Med Biol.* 2022 Dec 13;67(24). [[PubMed](#)]
37. Zhao L et al. An evolutionary optimization algorithm for proton arc therapy. *Phys Med Biol.* 2022 Aug 16;67(16). [[PubMed](#)]
38. Zhao L et al. The first direct method of spot sparsity optimization for proton arc therapy. *Acta Oncol.* 2023 Jan;62(1):48-52. [[PubMed](#)]

# Available resources

Learn more on IBA Campus, your proton therapy community

## What is DynamicARC

An overview by Craig Stevens, Chief of Radiation Oncology, Corewell Health, United States



## A Journey to DynamicARC: recent breakthrough and future roadmap

A presentation by Xuanfeng (Leo) Ding, Lead Medical Physicist, Corewell Health Proton Therapy Center, United States



## Complex IMPT and DynamicARC plan comparisons

Presentations from leading experts from Corewell Health and Baptist Health South Florida, United States



Contact us !



CLICK OR SCAN THE QR CODE  
TO CONTACT US AND GET  
YOUR ADDITIONAL RESOURCES



www.iba-worldwide.com



MID122779 - September 2024 EN - Copyright © 2024 by Ion Beam Applications, Belgium.  
IBA® and the IBA Logo are registered trademarks of Ion Beam Applications.

Visit us online at  
[www.iba-protontherapy.com](http://www.iba-protontherapy.com)



Life.  
Science.